August 24, 2008 -- In 2008, Dr. John Hoekman was a Ph.D. student in pharmaceutics who had just won a UW business plan competition and was granted $25,000 to start his company. It’s been ten years since the incorporation of Impel in 2008, and we’ve grown from just three devoted dreamers to...

Safety and Tolerability of POD-DHE (STOP-301) Trial to Explore Safety and Tolerability of Long-Term Intermittent Use of Intranasal Dihydroergotamine Mesylate Delivered via Precision Olfactory Delivery (POD®) Device STOP-301 Trial Recruiting More Quickly Than Expected, Company On-Track With 2019 NDA Filing SEATTLE, August 22, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company...

The International Association of Parkinsonism and Related Disorders world congress will be held in Lyon, France on 19-22 August. Dr. Stephen Shrewsbury, CMO will be presenting a poster on A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic (PK/PDyn) Study of INP103 (POD® L dopa) Administered in the...

Impel's Clinical Operations team will be attending the annual summer networking event of the Pacific Northwest Association of Clinical Research Professionals (ACRP). The event will be held Tuesday, August 7 at 5:30 - 7:30 PM at Chandler's Crabhouse on Lake Union.  For more information, visit the event webpage here....

SEATTLE, July 16, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory Affairs. In this capacity, Gold has extensive oversight of regulatory...

SEATTLE, June 26, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced new data from the Company’s investigational drug INP104 for acute migraine will be presented at the American Headache Society’s 60th Annual Meeting, June 28...

SEATTLE, June 22, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of INP104, a novel, dihydroergotamine...

The Impel team will be attending the 60th Annual American Headache Society meeting on June 28th - July 1 in San Francisco, CA. Our team will be made up of Jon Congleton, CEO; Steve Shrewsbury, CMO; Meghan Swardstrom, VP of Clinical Operations; Maria Jeleva, Associate Director of Clinical Operations; and Sutapa Ray, Business Development Manager....